BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Meet the rescue team behind the astronauts as Artemis II's launch approaches - 2Israel scales back use of top missile interceptors as Iran barrages persist
- 3Pick Your #1 breakfast food
- 4German unemployment rate falls to 6.4%, but 3 million still jobless
- 5Novo Nordisk cuts Wegovy price in South Africa for a second time
- Staggering Spots to Stargaze All over the Planet
- Presenting Nintendo's New Pastel Bliss Con Tones for Switch Gamers: 3 Smart Choices
- Indian Health Service is digging out of decades-old construction backlog for medical buildings
- Farmers call for French blockades over cow disease cull
- Swap The Amalfi Coast For This Low-Cost Ligurian Seaside Town
- 10 Asian Countries Perfect for Solo Female Travelers
- The next frontier in space is closer than you think – welcome to the world of very low Earth orbit satellites
- The Way to Recuperation: Defeating Dependence
- Europe’s Airlines Run Low on Fuel
